Parkinson Diagnostic Accuracy Varies With Duration
The rate of diagnostic accuracy is lower in early disease and higher in later disease and is improved by medication response and other factors.
The rate of accuracy for a clinical diagnosis of Parkinson disease (PD) is only 26% in untreated patients and patients with PD that is not clearly responsive to medication, according to the findings of a new study. The rate increases to 53% in patients with early PD (less than 5 years of disease duration) responsive to medication and to more than 85% in patients with medication-responsive PD of longer duration.
Adler and colleagues from the Parkinson’s Disease and Movement Disorders Center, Department of Neurology, and Department of Biostatistics, Mayo Clinic, Scottsdale, Arizona, and other centers conducted their study with data from the Arizona Study of Aging and Neurodegenerative Disorders to determine the predictive value of a clinical PD diagnosis. They used 2 clinical diagnostic confidence levels, PossPD (never treated or not clearly responsive to medications) and ProbPD (responsive to medications). Neuropathologic findings were used as the gold standard in determining the accuracy of diagnosis.
In 9 of 34 PossPD cases and 80 of 97 ProbPD cases, PD was confirmed based on the first visit. PD was confirmed in 8 of 15 ProbPD cases with less than 5 years of disease duration and in 72 of 82 cases with 5 years or more of disease duration. According to final diagnosis at time of death, 91 of 107 ProbPD cases had confirmed PD. Diagnostic accuracy was improved by medication response, motor fluctuations, dyskinesias, and hyposmia.
The study provides Class II evidence that a clinical diagnosis of PD identifies patients who will have pathologically confirmed PD, with sensitivity and specificity of 88% and 68%, respectively, the researchers stated. They noted that caution is needed when interpreting clinical studies of PD, especially studies of early disease that do not have autopsy confirmation, and that the need for a tissue or other diagnostic biomarker is reinforced.
The study was
In an
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025